| Literature DB >> 22085404 |
Mahmoud Sadeghi1, Isabella Eckerle, Volker Daniel, Ulrich Burkhardt, Gerhard Opelz, Paul Schnitzler.
Abstract
BACKGROUND: Hantaviruses of the family Bunyaviridae are emerging zoonotic pathogens which cause hemorrhagic fever with renal syndrome (HFRS) in the Old World and hantavirus pulmonary syndrome (HPS) in the New World. An immune-mediated pathogenesis is discussed for both syndromes. The aim of our study was to investigate cytokine expression during the course of acute Puumala hantavirus infection.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22085404 PMCID: PMC3259039 DOI: 10.1186/1471-2172-12-65
Source DB: PubMed Journal: BMC Immunol ISSN: 1471-2172 Impact factor: 3.615
Characteristics of 64 hantavirus-infected patients included in the study.
| Patients characteristics (n = 64) | |
|---|---|
| male | 67.2% |
| female | 32.8% |
| adult | 89.7% |
| children/adolescents (age < 18 years) | 10.3% |
| mean age, years ± SD | 38.6 ± 16.4 |
| mean hospitalization time, days ± SD | 6.7 ± 4.5 |
| mean time until admission, days ± SD | 5.8 ± 3.5 |
Sex, age, hospitalization time and mean time until admission to hospital are given.
Figure 1Comparison of seasonality (A) and age distribution (B) of hantavirus cases in Germany and our study cohort. Data source on nationwide patient data: Robert Koch Institute.
Mean laboratory values on admission and minimum/maximum values during hospitalization of the study group.
| parameter | value on admission ± SD | range | reference values |
|---|---|---|---|
| 4.2 ± 2.5 | 1.0 - 11.7 | 0.1 - 1.3 | |
| 5.5 ± 2.7 | 1.1 - 11.9 | 0.1 - 1.3 | |
| 168 ± 99 | 38 - 531 | 150 - 440 | |
| 143 ± 99 | 37 - 531 | 150 - 440 | |
| 57.1 ± 34.3 | 9.6 - 147.8 | < 5 | |
| 66.0 ± 37.1 | 10.5- 148.0 | < 5 | |
| 9.6 ± 3.2 | 4.7 - 16.4 | 4 - 10 | |
| 11.2 ± 3.1 | 4.7 - 19.9 | 4 - 10 | |
| 43.6 ± 25.7 | 14.0 - 156.0 | < 35 | |
| 80.9 ± 120.8 | 27.0 - 907.0 | < 35 | |
| 39.9 ± 24.0 | 10.0 - 113.0 | < 35 | |
| 93.0 ± 105.7 | 10.0 - 745 | < 35 | |
Results for important clinical laboratory markers during hantavirus infection are described.
Symptoms and clinical findings of hantavirus-infected patients.
| Symptoms | Frequency |
|---|---|
| fever | 85.9% |
| lumbalgia | 62.5% |
| headache | 54.7% |
| nausea | 45.6% |
| vomiting | 39.1% |
| abdominal pain | 35.9% |
| myalgia | 28.1% |
| dizziness | 25.0% |
| bradycardia | 26.3% |
| vision disturbance | 20.6% |
| diarrhea | 20.3% |
| cough | 21.9% |
| arthralgia | 16.6% |
| collaps | 10.9% |
| dyspnoea | 12.5% |
| proteinuria | 59/64 (92.2%) |
| hematuria | 48/64 (75.0%) |
| pathologic findings in chest x-ray | 18/43 (41.9%) |
| ascites | 10/35 (28.6%) |
| splenomegaly | 24/43 (55.8%) |
| hepatomegaly | 22/43 (51.2%) |
| kidney enlargement | 35/61 (57.4%) |
| pulmonary edema | |
| acute glaucoma attack | |
| severe neurological involvement | |
| exanthema | |
| abortion | |
| hepatitis | |
| interstitial nephritis | |
| seizure | |
| hypertensive urgency | |
| Liver vein congestion | |
The frequency of clinical symptoms and findings is shown to point out common and uncommon symptoms. Additionally, unusual clinical findings are depicted separately, these were found once in different patients, respectively.
Figure 2Detection of anti-. Three patients presented without any detectable anti-PUUV antibodies on admission but seroconversion was detected in follow-up samples.
Comparison of cytokines in early and late acute hantavirus infection and healthy controls.
| parameter | healthy controls | early phase | early phase* | late phase | p1 | p2 | p3 |
|---|---|---|---|---|---|---|---|
| 2.2±8.6 | 9.5±7.2 | 7.2±5.6 | 14 ±17 | 0.08 | |||
| 3.3±8.4 | 0.6±2.1 | 0.4±0.6 | 0.3±0.6 | 0.82 | 0.63 | 0.56 | |
| 1.1±1.6 | 7.8±9.8 | 8.2±6.1 | 2.6±2.4 | ||||
| 13±32 | 563±1809 | 444±1076 | 130±230 | 0.16 | |||
| 2.4±5.5 | 5.2±8.4 | 8.3±10.7 | 0.7±2.0 | 0.014 | 0.17 | ||
| 0.8±1.0 | 5.2±4.2 | 6.4±4.6 | 3.6±3.1 | ||||
| 4203±2132 | 23708±12207 | 21581±9068 | 32847±13513 | ||||
| 0.3±1.8 | 1.1±6.7 | 2.9±11.6 | 10.5±33.5 | 0.41 | 0.23 | 0.29 | |
Statistical significant differences between healthy controls, patients with early hantavirus infection and patients with late hantavirus infection are shown in bold.
All data are given as mean±1SD. p1 = early phase acute hantavirus infection (n = 64) vs. healthy controls; p2 = late phase acute hantavirus infection vs. healthy controls; p3 = early phase (n = 21) vs. late phase acute hantavirus infection. P-values were calculated using Mann-Whitney-U and Wilcoxon Signed-Rank tests. Adjustment for multiple testing was done according to the method of Bonferroni. Only p-values of <0.01 after adjustment were considered to be significant and are bold printed. *only early phase samples of patients for which a corresponding late phase sample was available. To exclude cytokine accumulation due to impairment of renal excretion function, cytokine/creatinine ratios were calculated.
Figure 3Cytokine expression in patients (n = 64) with acute hantavirus infection during the early phase of disease (average 6 days after onset of symptoms) versus healthy controls (n = 39). The line in the middle of each box represents the median. The lower and the upper edges of the box are the 1st and 3rd quartile, respectively. There was a significant increase of IL-2, IL-6, IL-8, TGF-β1 and TNF-α during early acute hantavirus infection versus healthy controls. To exclude accumulation of cytokines due to impairment of renal excretion function during the early phase of acute disease, cytokine/creatinine ratios from the respective serum creatinine of every sample were calculated. Significant boxplots (p < 0.05) are marked with *.
Figure 4Cytokine expression during early (average 6 days after onset of symptoms) and late phase (average 12 days after onset of symptoms) of acute hantavirus infection in 21 patients. The line in the middle of each box represents the median. The lower and the upper edges of the box are the 1st and 3rd quartile, respectively. There was a significant decrease of IL-6, IL-10 and TNF-α and a significant increase of TGF-β1. Significant boxplots (p < 0.05) are marked with *.
Correlation analysis of cytokine expression for creatinine/cytokine ratio, platelet/cytokine ratio and CRP/cytokine ratio.
| parameter | r | p |
|---|---|---|
| 0.337 | 0.005 | |
| 0.316 | 0.009 | |
| 0.560 | <0.001 | |
| -0.265 | 0.029 | |
| -0.396 | 0.001 | |
| -0.367 | 0.002 | |
| -0.391 | 0.003 | |
| 0.421 | <0.001 | |
| - 0.26 | 0.030 | |
| - 0.42 | <0.0001 | |
| - 0.30 | 0.017 | |
| 0.49 | <0.0001 | |
| 0.34 | 0.004 | |
| 0.46 | 0.0001 | |